Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.

Chen KTJ, Anantha M, Leung AWY, Kulkarni JA, Militao GGC, Wehbe M, Sutherland B, Cullis PR, Bally MB.

Drug Deliv Transl Res. 2019 Sep 3. doi: 10.1007/s13346-019-00674-7. [Epub ahead of print]

PMID:
31482519
2.

Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.

Chen KTJ, Gilabert-Oriol R, Bally MB, Leung AWY.

Pharm Res. 2019 Jun 24;36(9):125. doi: 10.1007/s11095-019-2654-z. Review.

3.

Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin.

Gilabert-Oriol R, Sutherland BW, Anantha M, Pallaoro A, Bally MB.

Drug Deliv Transl Res. 2019 Dec;9(6):1082-1094. doi: 10.1007/s13346-019-00651-0.

PMID:
31209826
4.

What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.

Leung AWY, Amador C, Wang LC, Mody UV, Bally MB.

Pharmaceutics. 2019 Mar 16;11(3). pii: E124. doi: 10.3390/pharmaceutics11030124. Review.

5.

Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats.

Shi M, Anantha M, Wehbe M, Bally MB, Fortin D, Roy LO, Charest G, Richer M, Paquette B, Sanche L.

J Nanobiotechnology. 2018 Oct 5;16(1):77. doi: 10.1186/s12951-018-0404-8.

6.

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.

Gilabert-Oriol R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB.

Int J Mol Sci. 2018 Sep 26;19(10). pii: E2922. doi: 10.3390/ijms19102922. Review.

7.

Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, Orlando KA, Lang JD, Hendricks WPD, Bally MB, Karnezis AN, Hass R, Underhill TM, Morin GB, Trent JM, Weissman BE, Huntsman DG.

Mol Cancer Ther. 2018 Dec;17(12):2767-2779. doi: 10.1158/1535-7163.MCT-18-0348. Epub 2018 Sep 19.

8.

Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.

Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB.

J Control Release. 2018 Sep 28;286:1-9. doi: 10.1016/j.jconrel.2018.07.025. Epub 2018 Jul 18.

9.

Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.

Prosser KE, Leung AWY, Harrypersad S, Lewis AR, Bally MB, Walsby CJ.

Chemistry. 2018 Apr 25;24(24):6334-6338. doi: 10.1002/chem.201800289. Epub 2018 Apr 6.

PMID:
29490115
10.

Development of a copper-clioquinol formulation suitable for intravenous use.

Wehbe M, Malhotra AK, Anantha M, Lo C, Dragowska WH, Dos Santos N, Bally MB.

Drug Deliv Transl Res. 2018 Feb;8(1):239-251. doi: 10.1007/s13346-017-0455-7.

11.

In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target.

Leung AWY, Veinotte CJ, Melong N, Oh MH, Chen K, Enfield KSS, Backstrom I, Warburton C, Yapp D, Berman JN, Bally MB, Lockwood WW.

Clin Cancer Res. 2017 Nov 1;23(21):6555-6566. doi: 10.1158/1078-0432.CCR-17-0700. Epub 2017 Aug 8.

12.

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Wehbe M, Lo C, Leung AWY, Dragowska WH, Ryan GM, Bally MB.

Invest New Drugs. 2017 Dec;35(6):682-690. doi: 10.1007/s10637-017-0488-2. Epub 2017 Jul 21.

13.

A Perspective - can copper complexes be developed as a novel class of therapeutics?

Wehbe M, Leung AWY, Abrams MJ, Orvig C, Bally MB.

Dalton Trans. 2017 Aug 22;46(33):10758-10773. doi: 10.1039/c7dt01955f. Review.

PMID:
28702645
14.

Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.

Wehbe M, Anantha M, Shi M, Leung AW, Dragowska WH, Sanche L, Bally MB.

Int J Nanomedicine. 2017 May 31;12:4129-4146. doi: 10.2147/IJN.S137347. eCollection 2017.

15.

Optimization of liposomal topotecan for use in treating neuroblastoma.

Chernov L, Deyell RJ, Anantha M, Dos Santos N, Gilabert-Oriol R, Bally MB.

Cancer Med. 2017 Jun;6(6):1240-1254. doi: 10.1002/cam4.1083. Epub 2017 May 23.

16.

Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles.

Popov J, Gilabert-Oriol R, Bally MB.

Eur J Pharm Biopharm. 2017 Aug;117:256-269. doi: 10.1016/j.ejpb.2017.04.024. Epub 2017 Apr 24.

PMID:
28450189
17.

The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.

Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG.

J Pathol. 2017 Jul;242(3):371-383. doi: 10.1002/path.4912. Epub 2017 Jun 2.

18.

In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB.

Drug Deliv Transl Res. 2017 Aug;7(4):544-557. doi: 10.1007/s13346-017-0380-9.

PMID:
28432657
19.

Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.

Baradaran-Heravi A, Niesser J, Balgi AD, Choi K, Zimmerman C, South AP, Anderson HJ, Strynadka NC, Bally MB, Roberge M.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3479-3484. doi: 10.1073/pnas.1620982114. Epub 2017 Mar 13. Retraction in: Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11885.

20.

A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.

Wehbe M, Malhotra A, Anantha M, Roosendaal J, Leung AWY, Plackett D, Edwards K, Gilabert-Oriol R, Bally MB.

J Control Release. 2017 Apr 28;252:50-61. doi: 10.1016/j.jconrel.2017.03.010. Epub 2017 Mar 10.

Supplemental Content

Loading ...
Support Center